Patients with primary central nervous system lymphoma (PCNSL) not fulfilling inclusion criteria for clinical trials represent an underreported population. Thirty-four consecutive PCNSL patients seen at our center between 2005 and 2019 exclusion therapeutic were analyzed (non-study patients) compared from the G-PCNSL-SG-1 (German Study Group 1) study (study patients), largest prospective multice...

Objectives A subset of primary central nervous system lymphoma (PCNSL) has been shown to undergo an early relapsed/refractory (R/R) period after first-line chemotherapy. This study investigated the pretreatment clinical and MRI features predict R/R in PCNSL, emphasizing apparent diffusion coefficient (ADC) values diffusion-weighted imaging (DWI). Methods retrospective for predicting PCNSL. Only...

PURPOSE The incidence of primary central nervous system lymphoma (PCNSL) is increasing. Therapeutic approaches remain controversial. An animal model that mimics the clinical situation would be useful for evaluating PCNSL biology and treatment. EXPERIMENTAL DESIGN Nude rats received intracerebral (caudate nucleus, n = 49) or intraventricular (n = 4) inoculation of human B-lymphoma cell line MC...

BACKGROUND Individuals infected by HIV are at an increased risk for developing non-Hodgkin's lymphomas (AIDS-NHL). In the highly active antiretroviral therapy (HAART) era, there has been a significant decline in the incidence of AIDS-associated primary central nervous system lymphoma (PCNSL). However, only a modest decrease in incidence has been reported for other AIDS-NHL subtypes. Thus, AIDS-...

Introduction: High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is now the preferred consolidation strategy for young PCNSL patients. The optimal conditioning regimen unknown. data suggests that BEAM (carmustine, etoposide, cytarabine, melphalan) ineffective, BCNU/TT (carmustine/thiotepa) well-tolerated treatment related mortality (TRM) 1%–3%, but late relapses are com...

Antigen presentation by tumor cells in the context of Human Leukocyte Antigen (HLA) is generally considered to be a prerequisite for effective immune checkpoint inhibitor therapy. We evaluated cell surface HLA class I, HLA class II and cytoplasmic HLA-DM staining by immunohistochemistry (IHC) in 389 classical Hodgkin lymphomas (cHL), 22 nodular lymphocyte predominant Hodgkin lymphomas (NLPHL), ...

PURPOSE OF REVIEW Approximately 50% of all patients with primary central nervous system lymphoma (PCNSL) are 60 years or older and may therefore be considered as elderly. Although the diagnostic work-up is basically the same in young and in elderly patients, therapeutic strategies vary considerably. Here, we review the characteristics of elderly PCNSL patients with a particular focus on advance...

Abstract OBJECTIVE To compare primary CNS lymphoma [PCNSL] and secondary [SCNSL] incidence by year, month, week, time between symptom onset, radiographic study, tissue diagnosis. BACKGROUND PCNSL is a rare non-Hodgkin’s B-cell confined to the central nervous system with an increased among immunocompromised patients immunocompetent patients.1 Epstein Barr Virus [EBV] infection usually accompanie...

Primary lymphoma of the central nervous system (CNS), including reticulum cell sarcoma, microglioma, and histiocytic lymphoma, represents less than 1% of all primary brain tumors. In the last 10 years, this tumor has tripled in frequency in the nonimmunosuppressed population. By 1991, the tumor will be the most common neurological neoplasm by virtue of the increase in sporadic occurrence and in...

Primary central nervous system (CNS) lymphoma is an unusual but increasingly frequent brain tumor being identified by neurologists. Considerable improvements in survival have been accomplished by the addition of chemotherapy to cranial radiotherapy. In addition, many patients achieve substantial disease free survival with chemotherapy alone, and survival is superior to radiotherapy alone. Curre...